Seminars in Oncology Nursing
Volume 22, Issue 2 , Pages 97-106 , May 2006

Treatment Approaches and Nursing Considerations For Non-Hodgkin’s Lymphoma

  • Jennifer Long

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jennifer Long, APRN, Whittingham Cancer Center, Norwalk Hospital, 24 Stevens St, Norwalk, CT 06856
    • ,
  • Linda Versea

References 

  1. American Cancer Society . Cancer Facts & Figures 2006 . Atlanta, GA: American Cancer Society; 2006;
  2. Peterson C , Kahl B . Follicular lymphoma (Management options in the era of targeted therapy) . Curr Treat Options n Lymphoma . 2005;6:297–308
  3. Winter J , Gascoyne R , Besien K . Low-grade lymphoma . Hematology . 2004;1:203–226
  4. Ardeshna KM , Smith P , Norton A , et al.   Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma (A randomized controlled trial) . Lancet . 2003;362:516–522
  5. Ghielmini M , Schmitz SF , Cogliatti SB , et al.   Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event -free survival and response duration compared with standard weekly x4 schedule . Blood . 2005;103:4416–4423
  6. Peterson BA , Petroni GR , Frizzera G , et al.   Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas (A study of the Cancer and Leukemia Group B) . J Clin Oncol . 2003;21:5–15
  7. Fisher RI , LeBlanc M , Press OW , et al.   New treatment options have changed the survival of patients with follicular lymphoma . J Clin Oncol . 2005;23:1–6
  8. Coiffier B . Which treatment for mantle cell lymphoma patients in 1998? . J Clin Oncol . 1998;16:3–5
  9. Hainsworth JD . Rituximab as first-line systemic therapy for patients with low-grade lymphoma . Semin Oncol . 2000;27:25–29
  10. Davis TA , Grillo-Lopez AJ , White CA , et al.   Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma (Safety and efficacy of re-treatment) . J Clin Oncol . 2000;18:3135–3143
  11. Savage DG , Cohen NS , Hesdorffer CS , et al.   Combined fludarabine and rituximab for low-grade lymphoma and chronic lymphocytic leukemia . Leuk Lymphoma . 2003;44:477–481
  12. Leonard JP , Coleman M , Ketas J , et al.   Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma . J Clin Oncol . 2005;23:5044–5051
  13. Ghielmini M , Schmitz SF , Cogliatti SB , et al.   Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule . Blood . 2004;102:4416–4423
  14. Keating M , Coutre S , Rai K , et al.   Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia . Clin Lymphoma . 2004;4:220–227
  15. Mellstedt H . Monoclonal antibodies in human cancer . Drugs Today . 2003;39:1–16
  16. Wahl RL . Tositumomab and I-131 therapy in non-Hodgkin’s lymphoma . J Nucl Med . 2005;46:128S–140S
  17. Oriuchi N , Higuchi T , Hanaoka H , et al.   Current status of cancer therapy with radiolabeled monoclonal antibody . Ann Nucl Med . 2005;19:355–365
  18. Press OW , Unger JM , Braziel RM . A phase 2 trial of CHOP chemotherapy followed by tositumumab/iodine-131 tositumomab for previously untreated follicular non-Hodgkin lymphoma (Southwest Oncology Group Protocol S9911) . Blood . 2003;102:1606–1612
  19. O’Connor OA . The emerging role of bortezomib in the treatment of indolent non-Hodgkin’s and mantle cell lymphomas . Curr Treat Options Oncol . 2004;5:269–281
  20. O’Connor OA , Wright J , Moskowitz C , et al.   Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma . J Clin Oncol . 2005;23:676–684
  21. Goy A , Younes A , Mclaughlin P , et al.   Phase II study of proteasome inhibitor bortezemib in relapsed or refractory B-cell non-Hodgkin’s lymphoma . J Clin Oncol . 2005;23:667–675
  22. Sutcliffe SB , Gospodarowicz MK , Bush RS , et al.   Role of radiation therapy in localized non-Hodgkin’s lymphoma . Radiother Oncol . 1985;4:211–223
  23. MacManus MP , Hoppe RT . Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University . J Clin Oncol . 1996;14:1282–1290
  24. Leukemia and Lymphoma Society. Available at: www.leukemia-lymphoma.org (accessed August 27, 2005).
  25. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology; Anemia. Available at http://www.nccn.com/professionals/physician_gls/PDF/fever.pdf.need (accessed January 10, 2006).
  26. American Society of Clinical Oncology Practice Guidelines. Available at http://www.asco.org (accessed January 10, 2006).
  27. National Comprehensive Cancer Network. The NCN Clinical Practice Guidelines in Oncology; Antiemesis. Available at http://www.nccn.com/professionals/physician_gls/PDF/antiemesis.pdf (accessed January 10, 2006).
  28. McGuire DB , Rubenstein EB , Peterson DE . Evidence-based guidelines for managing mucositis . Semin Oncol Nurs . 2004;20:59–66
  29. Bexxar product description. Available at http://www.bexxar.com (accessed January 10, 2006).
  30. Hohenstein M , King SE , Fiore JM , et al.   Patient specific vaccine therapy for non-Hodgkin’s lymphoma . Clin J Oncol Nurs . 2004;9:85–90
  31. Block A , Casselith BR , Holmes MD , et al.   In: Eating Well, Staying Well (During and After Cancer) . Atlanta, GA: American Cancer Society; 2004;p. 56–77
  32. Distress; Treatment Guidelines for Patients. Version1/July 2004. National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS); 2004. Available at http://www.nccn.com/professionals/physiciansgls/pdf/distress.pdf (accessed March 31, 2006).

PII: S0749-2081(06)00044-1

doi: 10.1016/j.soncn.2006.03.001

Seminars in Oncology Nursing
Volume 22, Issue 2 , Pages 97-106 , May 2006

Article Tools